Sumary of MIS-C displays clinical, proteomic heterogeneity, ‘outsized’ CXCL9 levels:
- November 15, 2021 2 min read Source/Disclosures Published by: Source: Behrens E.
- Source: Adobe Stock “Multisystem inflammatory syndrome in children, or MIS-C, is a post-infectious complication of pediatric SARS-CoV-2, typically occurring 3 to 4 weeks after asymptomatic exposure,” Edward Behrens, MD, of the Children’s Hospital of Philadelphia, told attendees at the virtual meeting.
- ” “It was originally recognized as a Kawasaki’s disease-like syndrome, with many patients also having coronary artery aneurisms or dilation,” he added.
- Using the Olink Explore 1536/384 protein biomarker platform, Behrens and colleagues interrogated the plasma proteome of all 88 patients.
- The researchers created a principal component analysis (PCA) that mapped all proteins and all patients in order to better understand how the overall proteome of patients with MIS-C changes over time.
- When they analyzed CXCL9 as the key protein associated with IFNg response, they found that all patients with COVID-19 demonstrated a positive CXCL9 response to increasing IFNg.
- MIS-C patients also expressed less TRIM21 protein compared to healthy patients, consistent with a derepression of IFNg signaling.
- According to Behrens, unsupervised hierarchical clustering revealed two distinct groups of patients with MIS-C demonstrating increases in multiple Macrophage Activation Syndrome (MAS) markers.